

# Singapore Results Review

5 August 2022

Financial Services | Banks

# **BUV** (Maintained)

SGD37.60 (16.0%)

DBS (DBS SP)

1H22: Robust NIM Expansion, Solid Asset Quality

Price (Market Cap): SGD32.40 (USD60,489m) 3.30 (out of 4) Avg Daily Turnover (SGD/USD) 133m/95.6m • Stay BUY, new SGD37.60 TP from SGD38.10, 16% upside with c.4.5% **Analyst** 

- FY22F yield. 1H22 earnings were within expectations, as positive NIM surprise offset non-II weakness. FY22F earnings are projected to rise by a robust 21% on continued NIM expansion in 2H22 and benign credit cost compensates for still subdued non-II. Share price has retreated 10% in the past six months on rising macroeconomic concerns. With FY23 ROE projected to rise to 15%, the current 1.4x FY22F P/BV valuation is compelling.
- 1H22 results in line. 1H22 earnings of SGD3.62bn (-3% YoY) accounted for 47% and 49% of our and Street's FY22F bottomline. Reported ROE was 13.3% (FY: 12.5%) while CET-1 was stable at 14.2%. An interim DPS of SGD0.36 was declared. In 2Q22, PPOP rose a modest 1% QoQ, as robust NII growth of 12% QoQ was negated by lower net fee income (-14%) and other non-II (-15%). CIR was stable at 43.7%. With provisions down 16% QoQ, net profit ticked up 1% QoQ. Specific provisions (SP) credit cost was 8bps (1Q22: 15bps) (see Figure 1).
- Loan growth guidance toned down. DBS expects US interest rates to peak at 3.5-4%, with inflation tempered and the US economy slipping into a mild recession. The flow-through to Asia is likely to be contained. That said, management sees some tail risks from geopolitical developments in Russia-Ukraine and China. Consequently, loan growth guidance is dialled down to mid-single digit from an earlier target of mid-to-high single digit.
- The bright spot remains tailwinds from sharper- and faster-than-expected hikes in the US Federal Funds Rate that will have a positive impact on NIM over two years. NIM, which has reached 1.80% in July (2Q22: 1.58%), is expected to rise above 2% by 4Q22. This compared with earlier guidance of 1.58-1.6% in FY22 with the exit rate at 1.8% (FY21: 1.45%). DBS reiterated that NII would rise by SGD18-20m on every 1bp hike in US rates.
- Fee income to remain subdued. Management believes fee income has bottomed in 2Q22. That said, uncertainty in capital markets would continue to weigh on the wealth management business as investors stay side-lined. Overall, fee income is expected to decline YoY in FY22.
- Asset quality resilient. Non-performing assets (NPA) was little changed in 2Q22. NPL ratio was stable QoQ at 1.27% and NPA coverage a comfortable 113% (4Q21: 116%). Having tightened its portfolios over the past two years, management believes customers would be able to absorb the higher interest rates. Exposure to China's real estate sector is a small SGD2bn with no stress detected. SP credit cost of 11bps in 1H22 is lower than FY22F guidance of 15-20bps (FY21: 12bps).
- Earnings and TP. We raised FY22F-24F earnings by 4-8% as we pencilled in higher NIMs, which helped offset downward revisions in non-II. Our TP is lowered to SGD37.60 as we raised the equity risk premium for geopolitical tensions and recessionary risks. Our TP incorporates a 4% ESG premium based on RHB's in-house methodology (Figure 4).

Forecasts and Valuation	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Reported net profit (SGDm)	4,721	6,805	8,228	9,180	9,406
Net profit growth (%)	(26.1)	44.1	20.9	11.6	2.5
Recurring net profit (SGDm)	4,721	6,805	8,228	9,180	9,406
Recurring EPS (SGD)	1.85	2.66	3.20	3.57	3.66
BVPS (SGD)	21.41	22.40	22.83	24.85	26.71
DPS (SGD)	0.72	1.20	1.47	1.62	1.83
Recurring P/E (x)	17.52	12.19	10.12	9.07	8.85
P/B (x)	1.51	1.45	1.42	1.30	1.21
Dividend Yield (%)	2.2	3.7	4.5	5.0	5.6
Return on average equity (%)	8.9	12.1	14.2	15.0	14.2

Source: Company data, RHB

Singapore Research sg.research@rhbgroup.com

Target Price (Return):

## **Share Performance (%)**

	YTD	1m	3m	6m	12m
Absolute	(0.8)	8.0	(4.8)	(9.9)	6.0
Relative	(5.5)	3.2	(2.4)	(8.0)	3.3
52-wk Price lov	v/high (SGD)			29.3	- 37.3



Source: Bloomberg

#### Overall ESG Score: 3.30 (out of 4)

#### E: GOOD

DBS' sustainability agenda is centred around three sustainability pillars - responsible banking, responsible business practices, and creating social impact. To encourage carbon-intensive companies to adopt more carbon-efficient operations, DBS published the Sustainable and Transition Finance Framework and Taxanomy, a first in the world by a bank. It aims to build a sustainable finance portfolio of SGD50bn by 2024 (2020: SGD9.6bn), and is committed to ensure net zero operational carbon emissions by 2022.

### S: EXCELLENT

DBS has a comprehensive approach to talent management and retention. As skills required in banking are fast evolving, DBS is doubling down on efforts to build a futureready workforce. In 2020, women accounted for 51% of total employees, 27% of the Board and 25% of its Group Management Committee. DBS has initiatives to on-board the underbanked, nurture healthy savings and investment habits, and provide financing to underserved businesses and customers.

## G: EXCELLENT

DBS has a multi-year roadmap to modernise its data governance programme. In Feb 2022, Monetary Authority of Singapore required DBS to set aside SGD930m additional regulatory capital for the disruption of its digital banking services.



# **Financial Exhibits**

Asia
Singapore
Financial Services
DBS
DBS SP

Buy

# Valuation basis

GGM-derived intrinsic value with an ESG overlay. Key GGM assumptions are:

- i. 14.8% ROE;
- ii. 10.5% COE;
- iii. 3% long-term growth.

#### Key drivers

Key earning drivers are:

- i. Credit cost;
- ii. NIM;
- iii. Fee income growth;
- iv. Loan growth.

### Key risks

Key risks are:

- i. Higher-than-expected credit cost
- ii. Weaker-than-expected NIM;
- iii. Execution risks related to integration of newly acquired assets.

### **Company Profile**

DBS is the largest Singapore bank by assets. It also has significant exposure to Greater China.

Financial summary (SGD)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
EPS	1.85	2.66	3.20	3.57	3.66
Recurring EPS	1.85	2.66	3.20	3.57	3.66
DPS	0.72	1.20	1.47	1.62	1.83
BVPS	21.41	22.40	22.83	24.85	26.71
Valuation metrics	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Recurring P/E (x)	17.52	12.19	10.12	9.07	8.85
P/B (x)	1.5	1.4	1.4	1.3	1.2
Dividend Yield (%)	2.2	3.7	4.5	5.0	5.6
Income statement (SGDm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Interest income	12,208	10,185	13,000	15,585	15,869
Interest expense	(3,132)	(1,745)	(2,640)	(3,534)	(3,379)
Net interest income	9,076	8,440	10,360	12,051	12,491
Non interest income	5,516	5,961	5,800	6,123	6,595
Total operating income	14,592	14,401	16,160	18,174	19,086
Overheads	(6,158)	(6,569)	(6,600)	(7,169)	(7,608)
Pre-provision operating profit	8,434	7,832	9,560	11,005	11,478
Loan impairment allowances	(3,063)	(51)	(100)	(450)	(600)
Other impairment allowances	(3)	(1)	-	-	-
Pre-tax profit	5,368	7,780	9,460	10,555	10,878
Taxation	(612)	(973)	(1,230)	(1,372)	(1,469)
Minority interests	(35)	(2)	(2)	(3)	(4)
Reported net profit	4,721	6,805	8,228	9,180	9,406
Recurring net profit	4,721	6,805	8,228	9,180	9,406

Profitability ratios	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Return on average assets (%)	0.8	1.0	1.1	1.1	1.1
Return on average equity (%)	8.9	12.1	14.2	15.0	14.2
Return on IEAs (%)	2.1	1.6	1.9	2.2	2.1
Cost of funds (%)	0.6	0.3	0.4	0.5	0.5
Net interest spread (%)	1.5	1.3	1.5	1.6	1.6
Net interest margin (%)	1.6	1.4	1.5	1.7	1.6
Non-interest income / total income (%)	37.8	41.4	35.9	33.7	34.6
Cost to income ratio (%)	42.2	45.6	40.8	39.4	39.9
Credit cost (bps)	82.8	1.3	2.3	10.0	12.7

Balance sheet (SGDm)	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Total gross loans	377,770	415,072	437,901	459,796	482,786
Other interest earning assets	218,641	230,708	259,050	289,603	311,216
Total gross IEAs	596,411	645,780	696,951	749,399	794,002
Total provisions	(6,599)	(6,079)	(6,300)	(6,550)	(6,800)
Net loans to customers	371,171	408,993	431,601	453,246	475,986
Total net IEAs	589,812	639,701	690,651	742,849	787,202
Total non-IEAs	60,126	46,372	102,791	90,530	86,180
Total assets	649,938	686,073	793,442	833,379	873,382
Customer deposits	464,850	501,959	538,000	564,900	595,970
Other interest-bearing liabilities	75,467	87,415	99,500	97,755	98,704
Total IBLs	540,317	589,374	637,500	662,655	694,673
Total non-IBLs	54,978	38,985	97,100	106,709	109,910
Total liabilities	595,295	628,359	734,600	769,364	804,583
Share capital	2,441	2,441	2,441	2,441	2,441
Shareholders' equity	54,626	57,526	58,647	63,820	68,603
Minority interests	17	188	195	195	196

Asset quality and capital	Dec-20	Dec-21	Dec-22F	Dec-23F	Dec-24F
Reported NPLs / gross cust loans (%)	1.6	1.3	1.3	1.3	1.3
Total provisions / reported NPLs (%)	108.9	114.9	112.4	109.6	107.9
CET-1 ratio (%)	13.9	14.4	14.9	14.8	14.5
Tier-1 ratio (%)	15.0	15.1	15.6	15.5	15.1
Total capital ratio (%)	16.9	17.0	17.2	16.9	16.3

Source: Company data, RHB



# **Results At a Glance**

FYE 31 Dec (SGDm)	2Q21	1Q22	2Q22	QoQ (%)	YoY (%)	1H21	1H22	YoY (%)	Comments: 1H22 vs 1H21
NII	2,089	2,187	2,454	12	17	4,196	4,641	11	Up YoY on healthy loan growth and better NIM.
NIM (%) – reported	1.45%	1.46%	1.58%			1.47%	1.52%		NIM up 5bps YoY as interest rate began to rise.
Non-II	1,500	1,560	1,338	-14	-11	3,247	2,898	-11	
Net fee & commission income	868	891	768	-14	-12	1,821	1,659	-9	Down YoY on lower fees from wealt management (-21% YoY) an investment banking (-36% YoY) These offset recovery in fees from loan-related, cards and transaction services.
Other non-II	632	669	570	-15	-10	1,426	1,239	-13	Down YoY on lower investment gains
Non-II/total income (%)	41.8%	41.6%	35.3%			43.6%	38.4%		
Operating income	3,589	3,747	3,792	1	6	7,443	7,539	1	
Overhead expenses	(1,543)	(1,644)	(1,658)	1	7	(3,130)	(3,302)	5	Staff cost rose 7% YoY on wag increases and higher headcount.
CIR (%)	43.0%	43.9%	43.7%			42.1%	43.8%		
PIOP	2,046	2,103	2,134	1	4	4,313	4,237	-2	
Impairments charges	(79)	(55)	(46)	-16	-42	(89)	(101)	13	Increase mainly due to lower while general provision write-backs of SGD135m vs SGD275m in 1H21 Specific provision were down 359 YoY.
Credit cost (bps) - SP	14	15	8			18	11		
Operating profit	1,967	2,048	2,088	2	6	4,224	4,136	-2	
Associates	-	-	-			-	-		
Pre-tax profit	1,967	2,048	2,088	2	6	4,224	4,136	-2	
Tax	(271)	(239)	(280)			(511)	(519)		
Effective tax rate (%)	13.8%	11.7%	13.4%			12.1%	12.5%		
Minorities	7	(8)	7			(1)	(1)		
Net profit	1,703	1,801	1,815	1	7	3,712	3,616	-3	1H22 earnings at 47% and 49% of ou and Street's FY22F bottomline.
Other key data and ratios									
Gross loans	403,460	422,000	430,677	2	7				Loans grew 3.8% YTD or a annualised 7.6%, led mainly by trad loans on rising commodity prices.
Customer deposits	482,837	519,723	527,828	2	9				Deposits grew 5.2% YTD or 10.49 annualised. CASA deposits wer flattish YTD. CASA ratio remained hig at 72%.
Non-performing assets	6,621	5,981	5,908	-1	-11				Loan NPLs were little changed QoO NPL ratio was stable at 1.27%.
Total assets	671,841	723,681	745,637	3	11				
Shareholders' funds	57,594	56,495	55,875	-1	-3				
ROAA (%)	1.03	1.04	0.99			1.14	1.02		
ROAE (%) - Reported	12.7	13.1	13.4			14.0	13.3		
LDR (%)	82.2	80.1	80.4			-	- <del>-</del>		
NPA ratio	1.51	1.30	1.27						
Loan loss coverage	106.7	114.0	111.9						
CET-1 ratio (%)	14.5	14.0	14.2						
Total capital ratio (%)	17.5	16.5	16.7						

Source: Company data, RHB

## Management guidance



Figure 2: DBS – management guidance and financial targets

	FY21 actual	1H22 achieved	2022 targets	Comments on FY22 targets
Loan growth (YoY)	+9.9%	+7%	Mid-single digit (from mid-single-digit or better)	Guidance toned down mainly due to difficulty projecting geopolitical developments in Russia-Ukraine and China. Pipelines remain healthy and management expects to add about SGD4-5bn per quarter in new loans for 2H22.
NIM	1.45%	1.52%	Above 2% by 4Q22 (from 1.58-1.60%)	Expects continued expansion in NIM with the sharp rise in US interest rates. Management guided for NII enhancement of SGD18-20m per bps of the US rate hike.
Fee income growth (YoY)	+15%	-9%	Negative growth (from double-digits growth)	Management believes fee income has bottomed in 2Q22. But with wealth fees expected to remain weak due to the uncertain capital markets, fee income for FY22 would be lower YoY.
Opex growth (%)	+5%	+5%	CIR of c.40% (from +6-7%)	Robust growth in NII, which will offset the decline in non-II, is now expected to result in positive JAWS in FY22 (revised from mild negative JAWS). Management expects CIR to improve to c.40% from 45.6% in FY21.
Provision allowances	SGD52m	SGD101m	SGD0-100m	Management expects asset quality to remain resilient as stress tests indicate ability of borrowers to absorb the rise in interest rates. Exposure to China's real estate sector is a small SGD2bn with bulk of lending to network customers. At end-2021, GP reserves were at SGD3.74bn, which includes an GP overlay of SGD1.8bn.

Source: Company data, RHB

## **Revisions to earnings estimates**

We upgraded FY22F-24F earnings by 4-8% as we raised assumptions on NIM, which more than offset cuts in non-II.

Figure 3: DBS – revisions to earnings forecasts

FYE Dec	Previous FY22F	Previous FY23F	Previous FY24F	Revised FY22F	Revised FY23F	New FY24F	% Change FY22F	% Change FY23F	% Change FY24F
(SGDm)									
NII	9,635	10,960	11,760	10,360	12,051	12,491	7.5%	10.0%	6.2%
Non-II	6,430	6,989	7,541	5,800	6,123	6,595	-9.8%	-12.4%	-12.5%
Operating expenses	(7,103)	(7,714)	(8,185)	(6,600)	(7,169)	(7,608)	-7.1%	-7.1%	-7.0%
PIOP	8,962	10,235	11,116	9,560	11,005	11,478	6.7%	7.5%	3.3%
Provision expenses	(100)	(450)	(600)	(100)	(450)	(600)	0.0%	0.0%	0.0%
Pre-tax profit	8,862	9,785	10,516	9,460	10,555	10,878	6.7%	7.9%	3.4%
Net profit	7,680	8,478	9,054	8,228	9,180	9,406	7.1%	8.3%	3.9%
EPS (SGD)	2.99	3.30	3.53	3.20	3.57	3.66			
DPS (SGD)	1.47	1.62	1.83	1.47	1.62	1.83			
Loan growth (%)	6.5	5.5	5.0	5.5	5.0	5.0			
NIM (%)	1.48	1.61	1.65	1.56	1.68	1.63			
CIR (%)	44.2	43.0	42.4	40.8	39.4	39.9			
Credit cost (bps)	2	10	13	2	10	13			

Source: Company data, RHB



### **Valuation and TP**

We lowered our TP to SGD37.60 from SGD38.10 based on an intrinsic value of SGD36.19 from SGD36.68 and a 4% ESG premium based on our in-house ESG methodology.

The revised intrinsic value is mainly due to the assumptions of a higher cost of equity and lower long-term growth on account of geopolitical tensions and recessionary risks. These offset assumptions of higher ROE and BVPS following the upgrade in FY22F-24F earnings.

The GGM-derived P/BV of 1.57x (unchanged) is above +1SD from the historical mean, against a multi-year high ROE of above 13%.


Figure 4: DBS - GGM valuation

Cost of equity (COE) computation:		Sustainable ROE (%)	14.80
Risk free rate (%)	2.65	COE (%)	10.50
Equity premium (%)	7.85	Long-term growth (g)	3.00
Beta (x)	1.00	Implied P/BV (x)	1.57
Cost of equity - CAPM (%)	10.0	BVPS - rolling 12-mth forward	SGD23
		Intrinsic value	SGD36.19
ESG premium/(discount) (%)	4.0	ESG premium/(discount)	SGD1.45
		TP (rounded)	SGD37.60

Source: Company data, RHB

Figure 5: DBS' 12-month forward consensus P/E

Figure 6: DBS' 12-month forward consensus P/BV



Source: Bloomberg, RHB Source: Bloomberg, RHB



# **Recommendation Chart**



Source: RHB, Bloomberg

Date	Recommendation	Target Price	Price
2022-05-03	Buy	38.1	33.9
2022-02-14	Buy	42.7	37.2
2021-11-07	Buy	40.4	32.3
2021-08-05	Buy	35.5	30.8
2021-05-02	Buy	34.0	29.9
2021-03-30	Buy	33.0	29.0
2021-02-10	Buy	30.0	26.0
2020-12-09	Buy	30.0	25.5
2020-11-05	Buy	25.2	22.4
2020-08-07	Neutral	18.5	20.6
2020-04-30	Neutral	18.7	20.0
2020-03-12	Neutral	21.5	20.2
2020-02-13	Neutral	24.8	25.4
2020-02-13	Neutral	25.8	25.4
2020-02-13	Neutral	24.8	25.4

Source: RHB, Bloomberg

# **ESG** Rating History



Source: RHB

#### **RHB Guide to Investment Ratings**

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next

12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels Sell: Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

#### **Investment Research Disclaimers**

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

### RESTRICTIONS ON DISTRIBUTION

### Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

#### Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a



member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

#### **United States**

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

## DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Save as disclosed in the following link RHB Research conflict disclosures – Jul 2022 and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
  RHBIB is not a market maker in the securities or capital market products of the
- subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member\* of the subject company(ies) covered in this report \*For the avoidance of doubt, the confirmation is only limited to the staff of research
- RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Save as disclosed in the following link RHB Research conflict disclosures -

- RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
   RHB Securities (Thailand) PCL is not a market maker in the securities or capital
- market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member\* of the subject company(ies) covered in this report
- \*For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

#### Indonesia

Save as disclosed in the following link RHB Research conflict disclosures – Jul 2022 and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report. For the avoidance of doubt, interest in securities include the following:
  - a) Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the
  - subject company's securities covered in this report\*;
    Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities\*
  - Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering\*.
  - Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital
- market products of the subject company(ies) covered in this report.

  None of PT RHB Sekuritas Indonesia's staff\*\* or associated person serve as a director or board member\* of the subject company(ies) covered in this report.
- PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- PT RHB Sekuritas Indonesia\*\* did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

#### Notes:

\*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

\*The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

#### Singapore

Save as disclosed in the following link RHB Research conflict disclosures – Jul 2022 and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
- 3. RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- 5. RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research analysts do not receive any compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysts.

#### **Analyst Certification**

The analyst(s) who prepared this report, and their associates hereby, certify that:



(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	=

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



### **KUALA LUMPUR**

#### **RHB Investment Bank Bhd**

Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel: +603 9280 8888 Fax: +603 9200 2216

#### **BANGKOK**

## **RHB Securities (Thailand) PCL**

10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand

Tel: +66 2088 9999 Fax:+66 2088 9799

### **JAKARTA**

#### PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia

Tel: +6221 509 39 888 Fax: +6221 509 39 777

#### **SINGAPORE**

## RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470